Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177940 · ClinicalTrials.gov registry record · Phase 4
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
A Phase 4 study of Osteoporosis, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04177940 is a Phase 4 study of Osteoporosis that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 45 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04177940, a Phase 4 study of Osteoporosis, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last denosumab dose) compared to participants randomized to "early" zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose).
Conditions Studied
Interventions
- DRUG DMAB Discontinuation and Switching
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177940
The ClinicalTrials.gov registry entry for NCT04177940 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which DMAB Discontinuation and Switching is the first listed.
NCT04177940 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT04177940 about?
NCT04177940 is a clinical study titled "Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study". Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last d...
What is the current status of trial NCT04177940?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2020-08-17. Estimated completion is 2025-08-31.
What conditions does trial NCT04177940 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT04177940?
The interventions under investigation include: DMAB Discontinuation and Switching (DRUG).
Who is sponsoring clinical trial NCT04177940?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04177940 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Muscle Impact of Treating Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.